CD20+ and CD8+ TIL synergistically mediate anti‐tumor immunity in ovarian cancer, thereby significantly prolonging survival, suggesting that TIL‐Bs support the T lymphocyte response to cancer [49]. Here, CD8A is linked to ovarian cancer.